Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Short term Debt (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Short term Debt data on record, last reported at $923000.0 in Q3 2025.

  • For Q3 2025, Short term Debt rose 266.27% year-over-year to $923000.0; the TTM value through Sep 2025 reached $923000.0, up 266.27%, while the annual FY2024 figure was $234000.0, 46.33% down from the prior year.
  • Short term Debt reached $923000.0 in Q3 2025 per AMPH's latest filing, roughly flat from $927000.0 in the prior quarter.
  • Across five years, Short term Debt topped out at $12.9 million in Q2 2023 and bottomed at $224000.0 in Q1 2025.
  • Average Short term Debt over 5 years is $2.8 million, with a median of $1.7 million recorded in 2022.
  • Peak YoY movement for Short term Debt: soared 528.1% in 2023, then crashed 98.07% in 2024.
  • A 5-year view of Short term Debt shows it stood at $2.2 million in 2021, then surged by 38.33% to $3.0 million in 2022, then plummeted by 85.69% to $436000.0 in 2023, then plummeted by 46.33% to $234000.0 in 2024, then surged by 294.44% to $923000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Short term Debt were $923000.0 in Q3 2025, $927000.0 in Q2 2025, and $224000.0 in Q1 2025.